Cargando…
Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials
SUMMARY: We evaluated the influence of baseline age, bone mineral density (BMD), and serum levels of vitamin D on the response to risedronate treatment. Risedronate consistently increased BMD, but our results suggest vitamin D supplementation may be necessary to achieve optimal treatment effect. Fur...
Autores principales: | Mawatari, T., Muraoka, R., Iwamoto, Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357292/ https://www.ncbi.nlm.nih.gov/pubmed/27900428 http://dx.doi.org/10.1007/s00198-016-3848-4 |
Ejemplares similares
-
Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial
por: Mawatari, Taro, et al.
Publicado: (2020) -
Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
por: Shigematsu, Takashi, et al.
Publicado: (2017) -
Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan
por: Inoue, Daisuke, et al.
Publicado: (2015) -
Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010) -
Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
por: Bobba, Raja, et al.
Publicado: (2007)